Bone Marrow Reconstitution With Chemotherapy-Resistant Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional myeloablative bone marrow transplants cause significant side effects and prolonged recovery due to the killing of both healthy and unhealthy cells, leading to susceptibility to infections and other complications, particularly in young patients.
Innovation Solution
A non-myeloablative bone marrow transplant method using chemotherapeutic-resistant modified stem cells, such as those expressing ALDH1, is administered with a non-myeloablative dose of chemotherapeutic agents like cyclophosphamide, allowing bone marrow reconstitution without irreversible cytopenia, thereby reducing toxicity and infection risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If myeloablative chemotherapy and radiation are used to kill cells in bone marrow, then unhealthy cells are eliminated, but healthy immune and stem cells are also killed causing susceptibility to infections and prolonged recovery
Solution Approach 1:
The patent segments the bone marrow cell population into unhealthy cells (target for elimination) and healthy cells (to be preserved). By using lower doses of chemotherapy and radiation that selectively target unhealthy cells while sparing healthy stem and immune cells, the treatment achieves cell elimination without causing severe immunosuppression and infection susceptibility.
Solution Approach 2:
The patent changes the dosage parameters of chemotherapeutic agents from myeloablative (high-dose) to non-myeloablative (low-dose) levels. This parameter change allows the treatment to eliminate unhealthy cells through selective toxicity while maintaining the functional integrity of healthy bone marrow cells, thereby reducing infection risk and shortening recovery time.
2Reliability
If high doses of chemotherapy are administered to treat disease, then treatment efficacy is improved, but severe side effects including cataracts, growth retardation, and cardiotoxicity occur
Solution Approach 1:
The patent applies partial action by using sub-myeloablative doses of chemotherapeutic agents that are sufficient to eliminate unhealthy bone marrow cells but insufficient to cause the severe tissue damage and long-term side effects associated with full myeloablative dosing. This partial dosing strategy maintains treatment efficacy while avoiding excessive toxicity.
Solution Approach 2:
The patent converts the selective toxicity of chemotherapeutic agents into a benefit by using doses that exploit the differential sensitivity between unhealthy and healthy cells. The harmful potential of high-dose chemotherapy is transformed into a controlled therapeutic effect that eliminates disease-causing cells while preserving healthy tissue through carefully selected lower dosing regimens.
3Reliability
If myeloablative bone marrow transplantation is performed, then bone marrow reconstitution is achieved, but patients require prolonged hospitalization and sterile environment maintenance
Solution Approach 1:
The patent performs preliminary protection of healthy bone marrow cells before chemotherapy administration by using lower doses that inherently spare these cells. This preliminary protective approach eliminates the need for prolonged post-treatment isolation and sterile environment maintenance, as healthy stem and immune cells remain functional and can immediately begin reconstitution processes.
Solution Approach 2:
The non-myeloablative chemotherapy regimen serves multiple functions simultaneously: it eliminates unhealthy bone marrow cells, preserves healthy stem and immune cells, and enables rapid bone marrow reconstitution without requiring prolonged hospitalization. This multi-functional approach consolidates several therapeutic goals into a single treatment strategy.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and/or an impaired immune system.